Do you have a view on the dose rationale, in vivo, for the use of this bryostatin derivative in AD? Has the company ever discussed this point, I have not been able to find it regarding NRTP?
Further, any discussion about CMC procedures and issues therein? The company has not discussed this to my satisfaction either.
News 
Market Data 
Discover 
